Could MDMA-Assisted Therapy Help Treat Anorexia?
A Toronto psychedelic therapy clinic has been selected as a trial site for a new study on MDMA-assisted therapy for eating disorders.
Can MDMA-assisted therapy help treat eating disorders, like anorexia? That’s what a new study, funded by the U.S.-based non-profit Multidisciplinary Association for Psychedelic Studies (MAPS), is looking to find out.
While the safety and efficacy of MDMA-assisted therapy is still being investigated (and it is not approved by Health Canada for treatment of any mental health conditions), Ronan Levy, founder of Canadian mental wellness company Field Trip Health – the Toronto location of which has been selected as one of the trial sites for the study – points to previous studies that showed promise in the treatment for those diagnosed with PTSD. In a phase two trial conducted by MAPS, 54 percent of participants in the active treatment group no longer qualified for a diagnosis of PTSD after completi
KCSA Strategic Communications an integrated strategic communications firm specializing in public relations, investor relations and social media, today announced that it will host its inaugural virtual Psychedelics Investor Conference on Tuesday, January 26, 2021 and Wednesday, January 27, 2021 from 9:00am 12:30pm ET . This two-day event will feature presentations by eminent psychedelics companies and industry .
SARASOTA – In Rick Doblin’s version of a brave new world, within reach of the next generation, 10,000 psychedelic clinics will speckle the American landscape. Laws will regulate behavior, not access to drugs that “change consciousness.” Jails will no longer be filled with people who seek mind-bending remedies for personal ordeals.
And with those markers in place, 2070 will be the year “where we reach the point of what we call zero net trauma.”
“You know how people are talking about net zero carbon?” he says from his home in Boston. “We’re suffering from multigenerational trauma, trauma from wars, economic injustice, prejudice. The world is in crisis right now, from global warming, where we could be looking at hundreds of millions of climate refugees within a few decades.
E-Mail
IMAGE: Rachel Yehuda, PhD, Director of the Center for Psychedelic Psychotherapy and Trauma Research and Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai. view more
Credit: Mount Sinai Health System
The Icahn School of Medicine at Mount Sinai has launched a new center for psychedelics research. The Center for Psychedelic Psychotherapy and Trauma Research pursues a multipronged clinical and research approach to discovering novel and more efficacious therapies for post-traumatic stress disorder (PTSD), depression, anxiety, and other stress-related conditions in the veteran and civilian population. The Center will focus on studying MDMA, psilocybin, and other psychedelic compounds.